Baricitinib for uveitis that has not responded to earlier treatments
Tests baricitinib in adults with hard-to-treat non-infectious uveitis affecting the back of the eye.
Key facts
- Who runs it
- University Hospital, Rouen
- Where
- France6 sites in 1 countryChoose a country to see its sites
- Registry title
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 33 people, planned
- Started
- Jul 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- Baricitinib 4 MG
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-infectious uveitis (eye inflammation) that is not only in the front of the eye. Their uveitis must not have improved enough with at least one biotherapy.
- Age
- 18 Years to 75 Years
- Sex
- All
- Disease stage
- Active non-infectious, non-anterior uveitis, refractory (not responding) to at least one line of biotherapy.
- Earlier treatment
- Must have had at least one biotherapy (anti-TNF alpha, tocilizumab) that did not work well enough. Biotherapy and conventional immunosuppressive drugs (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) must be stopped for at least 10 days before joining. People who had JAK inhibitors before cannot join.
Main reasons for not taking part
- Uveitis only in the front of the eye, or uveitis caused by an infection
- Severe uveitis that threatens sight and needs urgent intravenous corticosteroids
- Vision worse than 1.3 LogMAR in at least one eye, or sight in only one eye
- Corticosteroid injection in the eye within 1 month, or a steroid implant within 3 months
- Cancer within the past 5 years (except some non-spreading skin cancers), or past blood clots in the veins
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patient with diagnosis of non-anterior non-infectious uveitis, refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab)
- Need to stop biotherapy (anti-TNF alpha or tocilizumab) and conventional immunosuppressive drugs (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) for at least 10 days prior to the inclusion date
Who cannot take part
- 1. Isolated anterior uveitis. 2. Infectious uveitis. 3. Severe uveitis threatening the visual prognosis and requiring emergency treatment with intravenous corticosteroids; Initial visual acuity > 1.3 LogMAR in at least one eye. 5. Corneal or lens opacity that prevents fundus visualization or may require cataract surgery during the study; Contraindication to baricitinib (OLUMIANT 2 and 4 mg film-coated tablets) : Hypersensitivity to the active substance or to any of the excipients; Contraindication to mydriasis. 8. Refractory glaucoma in either eye. 9. Monophthalmic patient. 10. Previous treatment with JAK inhibitors. 11. Intraocular corticosteroid injection (subconjunctival or laterobulbar) within 1 month prior to inclusion or intravitreal corticosteroid implant within 3 months prior to inclusion; Need for treatment with a biotherapy (anti-IL6, anti-IL6 receptor, anti-IL1, anti-IL12/IL23 anti-IL17, anti-BAFF) for extra-ocular involvement, during the entire study period; Treatment with OAT3 inhibitors with high inhibitory potential such as probenecid, leflunomide, teriflunomide 14. 14. Vaccination with a live or live attenuated vaccine within 15 days prior to inclusion 15. History of cancer within the previous 5 years, except non-metastatic squamous cell and basal cell carcinoma of the skin; Personal history of venous thromboembolic disease
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment
The group in the trial
- Patient treated with baricitinibTreatment being tested
Patient treated with baricitinib at a dose of 4 mg per day, taken orally in the morning, with one tablet per day for 6 months.
Treatment: Baricitinib 4 MG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
- Plain-language title
- Baricitinib for uveitis that has not responded to earlier treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT05651880, who can take part
- Record updated
- 8 June 2026